Search for dissertations about: "peptide receptor radionuclide therapy"
Showing result 1 - 5 of 17 swedish dissertations containing the words peptide receptor radionuclide therapy.
-
1. Peptide Receptor Radionuclide Therapy in Neuroendocrine Neoplasms : Aspects of tumour characteristics, receptor recycling and peptide mass
Abstract : Neuroendocrine neoplasm (NEN) can arise in any part of the body, but most commonly in the lungs, bronchi, and the gastrointestinal tract including the pancreas. They combine neuroendocrine and tissue-of-origin-specific characteristics; explaining different symptoms depending on the organ of origin. READ MORE
-
2. Aspects on Diagnosis and Treatment of Gastrointestinal Neuroendocrine Tumours
Abstract : Aspects on Diagnosis and Treatment of Gastrointestinal Neuroendocrine Tumours Background. Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) originate from endocrine cells of the intestinal mucosa and pancreas. READ MORE
-
3. Strategies for optimisation of 177Lu-octreotate therapy – exploring local administration and combination therapy regimens
Abstract : Neuroendocrine tumours (NETs) are a group of heterogeneous tumour types that originate in hormone-producing organs. Patients with NETs are often diagnosed after the primary tumour has metastasised. READ MORE
-
4. Computational patient models for simulation of dynamic gamma-camera imaging : Application to renography and peptide receptor radionuclide therapy
Abstract : Many nuclear medicine investigations rely on gamma-camera imaging to study and quantify the distribution of radiopharmaceuticals or radionuclides in the patient as a function of time. This is typically used for diagnostic studies of physiological functions or for calculation of absorbed doses following radionuclide therapy. READ MORE
-
5. 177Lu-DOTA-octreotate Radionuclide Therapy of Neuroendocrine Tumours : Dosimetry-Based Therapy Planning and Outcome
Abstract : Peptide receptor radionuclide therapy for the internal radiation of neuroendocrine tumours expressing somatostatin receptors has made great advances and offers promising results. 177Lu-DOTA-octreotate is one of the most widely used radiopeptides, but kidneys and bone marrow are organs at risk. READ MORE